,,REQUITE,PRO-CTCAE®

Thomas Jordan1,2,3, Thitikorn Nuamek2, Isabella Fornacon-Wood1,2

  • 1Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.

Frontiers in oncology
|April 25, 2024
PubMed
概括

调整后的REQUITE问卷显示出与临床医生的评估更好的一致性,肺癌患者更喜欢它而不是PRO-CTCAE®. 推REQUITE用于肺癌护理的常规临床使用.